IQV IQVIA HOLDINGS INC.
Services-Commercial Physical & Biological Research · NYSE · SEC CIK 1478242 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY8.8%
TTM net income YoY8.7%
TTM EPS YoY13.1%
Revenue 3-yr CAGR5.2%
Net income 3-yr CAGR7.7%
Margins
Gross margin33.1%
Operating margin12.8%
Net margin8.1%
FCF margin12.0%
EBITDA margin19.9%
Returns
ROE21.7%
ROA4.7%
ROIC (approx.)9.3%
Asset turnover0.58x
Leverage & solvency
Liabilities / assets77.7%
Debt / equity2.41x
Current ratio0.83x
Interest coverage2.83x
Cash quality & payout
Operating cash flow / net income1.96x
Accruals ratio-4.5%
Payout ratio—
Capex / revenue3.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $16.31B | $15.40B | $14.98B | $14.41B | $13.87B |
| Cost of revenue | $10.88B | $10.03B | $9.74B | $9.38B | $9.23B |
| Gross profit | $5.43B | $5.38B | $5.24B | $5.03B | $4.64B |
| SG&A expense | $2.00B | $1.99B | $2.05B | $2.07B | $1.96B |
| Operating income | $2.18B | $2.20B | $1.98B | $1.80B | $1.39B |
| Interest expense | $729.00M | $670.00M | $672.00M | $416.00M | $375.00M |
| Pretax income | $1.59B | $1.67B | $1.46B | $1.36B | $1.13B |
| Income tax | $252.00M | $301.00M | $101.00M | $260.00M | $163.00M |
| Net income | $1.36B | $1.37B | $1.36B | $1.09B | $966.00M |
| EBITDA | $3.33B | $3.32B | $3.10B | $2.93B | $2.66B |
| EPS (basic) | 7.91 | 7.57 | 7.39 | 5.82 | 5.05 |
| EPS (diluted) | 7.84 | 7.49 | 7.29 | 5.72 | 4.95 |
| Weighted avg. shares (diluted) | 173.50M | 183.40M | 186.30M | 190.60M | 195.00M |
| Balance sheet | |||||
| Cash & equivalents | $1.98B | $1.70B | $1.38B | $1.22B | $1.37B |
| Short-term investments | $161.00M | $141.00M | $120.00M | $93.00M | $111.00M |
| Receivables | $3.40B | $3.20B | $3.38B | $2.92B | $2.55B |
| Current assets | $6.25B | $5.83B | $5.60B | $4.98B | $4.76B |
| PP&E, net | $533.00M | $535.00M | $523.00M | $532.00M | $497.00M |
| Goodwill | $16.62B | $14.71B | $14.57B | $13.92B | $13.30B |
| Intangibles | $4.96B | $4.50B | $4.84B | $4.82B | $4.94B |
| Total assets | $29.94B | $26.90B | $26.68B | $25.34B | $24.69B |
| Current liabilities | $8.34B | $6.96B | $6.49B | $5.58B | $5.24B |
| Short-term debt | $1.84B | $1.15B | $718.00M | $152.00M | $91.00M |
| Long-term debt | $13.88B | $12.84B | $12.96B | $12.60B | $12.03B |
| Total debt | $15.72B | $13.98B | $13.67B | $12.75B | $12.12B |
| Total liabilities | $23.31B | $20.83B | $20.57B | $19.57B | $18.65B |
| Shareholders' equity | $6.50B | $6.07B | $6.11B | $5.76B | $6.04B |
| Net debt | $13.74B | $12.28B | $12.30B | $11.53B | $10.76B |
| Shares outstanding | 169.60M | 176.10M | 181.50M | 185.70M | 190.60M |
| Cash flow statement | |||||
| Operating cash flow | $2.65B | $2.72B | $2.15B | $2.26B | $2.94B |
| Capital expenditure | $603.00M | $602.00M | $649.00M | $674.00M | $640.00M |
| Free cash flow | $2.05B | $2.11B | $1.50B | $1.59B | $2.30B |
| Investing cash flow | -$2.31B | -$1.44B | -$1.60B | -$2.01B | -$2.10B |
| Financing cash flow | -$150.00M | -$878.00M | -$382.00M | -$329.00M | -$1.24B |
| Depreciation & amortization | $1.14B | $1.11B | $1.12B | $1.13B | $1.26B |
| Stock-based compensation | $247.00M | $206.00M | $217.00M | $194.00M | $170.00M |
| Share buybacks | $1.24B | $1.35B | $992.00M | $1.17B | $406.00M |
Free plan shows the latest 5 periods; Pro shows all 15 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.